Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice
Nonfactor therapies (NFTs) such as emicizumab are increasingly becoming established for bleed prophylaxis in people with hemophilia A. Both classes of bypassing agents (BPAs; activated prothrombin complex concentrate [aPCC] and recombinant activated factor [F]VII [rFVIIa]) are required for effective...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S247503792500250X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|